Hidradenitis Suppurativa

Status: draft compiled 2026-04-20.

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterised by painful recurrent nodules, abscesses, and tracts in apocrine-gland-bearing skin (axilla, groin, inframammary, buttock, perineum). Laser hair removal is an evidence-supported adjunct to standard HS care (topical clindamycin, oral doxycycline or clindamycin-rifampin, biologics such as adalimumab) and is now part of guideline-based HS management for Hurley stage I-II disease. The mechanism is combined: destruction of hair follicles (which are central to HS pathophysiology), reduction of inflammatory signalling in the affected field, and possibly direct antimicrobial heating of the dermal environment.

The evidence

Laser hair removal for HS — specifically long-pulsed Nd:YAG 1064 nm — has a small but consistent RCT base.

• Mahmoud BH, Tierney E, Hexsel CL, Pui J, Ozog DM, Hamzavi IH 2010, JAAD 62:637-645, PMID 19438670 — prospective controlled clinical and histopathologic study of HS treated with long-pulsed Nd:YAG. This is the primary controlled trial and the reference citation for most subsequent recommendations.
• Xu LY et al 2011, histopathologic series, JAMA Dermatology, PMID 20855672 — confirmed the mechanism by histologic assessment.
• 2024 alexandrite RCT in JAAD International — extends the evidence base to alexandrite wavelength for HS.
• 2025 systematic review in Journal of Clinical Medicine 14(21):7683 — updated review of laser in HS; supports long-pulsed Nd:YAG and alexandrite as adjunct.

Hurley stage I-II (limited number of lesions without extensive scarring or tract formation) is the stage at which laser is most effective. Hurley stage III (diffuse disease with interconnected tracts) is less responsive to laser alone and typically requires surgical excision. Confidence: C2.

Protocol

Standard regimen: long-pulsed Nd:YAG 1064 nm, monthly sessions × 3-4 initially, then maintenance every 2-3 months. Parameters similar to standard hair removal for the skin type (20-40 ms pulse, 10-12 mm spot, 30-50 J/cm² for Fitz IV-V, adjusted for specific patient). Alexandrite at appropriate skin type is an alternative.

The treatment field includes the affected body regions plus surrounding transitional zone to eliminate the follicular substrate on which new lesions form. Patients often require multi-year commitment to see full benefit; durability depends on maintenance sessions and on concurrent medical therapy. Confidence: C3.

Integration with medical management

Laser is not a replacement for medical HS management but a complement to it. Standard medical care (topical clindamycin 1%, oral doxycycline 100 mg BID or minocycline 100 mg BID, clindamycin + rifampin for more severe disease, adalimumab for moderate-to-severe HS) continues through laser treatment. Acute flares are managed as they would be without laser. Patients on biologics may require temporary discontinuation around surgical interventions but typically continue biologics through laser courses.

The key clinical benefit of laser added to medical therapy is reduction in the frequency of new lesions in the treated field and reduction in the inflammatory burden over time. Patients who achieve good control with combined regimens often require fewer acute intervention episodes (incision and drainage, steroid injections, surgical excision) than patients on medical therapy alone. Confidence: C3.

Why this works

The HS pathophysiology centres on follicular occlusion in apocrine-gland regions, leading to follicular rupture, inflammatory cascade, and secondary bacterial colonisation. Destroying hair follicles in the affected field removes the anatomical substrate for new lesions and reduces the total inflammatory surface. Nd:YAG 1064 nm also produces bulk dermal heating that has been argued to have anti-inflammatory effects independent of follicular destruction, though the mechanistic evidence for this is thinner than for the follicle-based mechanism. Confidence: C3.

Patient selection

Best candidates:

• Hurley stage I-II disease with discrete lesions rather than interconnected tracts.
• Affected regions suitable for laser (axilla, groin, inframammary — all standard body regions for hair removal).
• Willingness to commit to monthly sessions × 3-4 plus maintenance over months to years.
• On stable medical management: topical clindamycin, doxycycline or minocycline, adalimumab as appropriate.

Less good candidates:

• Hurley stage III with extensive scarring or tract formation — surgical excision more appropriate.
• Acute flare at time of proposed session — defer until flare settles.
• Inadequate response to medical management alone — medical optimisation before laser is appropriate.

Confidence: C3.

Insurance coverage

HS-indicated laser hair removal has a clearer path to insurance coverage than cosmetic hair removal because the indication is clearly medical. ICD-10 L73.2 (hidradenitis suppurativa) supports medical-necessity framing. Documentation requirements typically include failed conservative therapy, photograph documentation of lesions, and a dermatologist's letter supporting the medical necessity. Coverage is available in most US commercial plans and in state Medicaid with appropriate documentation; the approval rate is higher than for PFB-indicated laser in most systems. Confidence: C3.

Future directions

Research directions in 2024-2026 laser hair removal for HS include:

• Alexandrite for HS on appropriate skin types — supported by the 2024 JAAD International RCT; expected to become the preferred choice for Fitz I-III HS where Nd:YAG is deeper than needed.
• Laser + biologic combinations — no RCT specifically, but combination regimens (adalimumab + laser) are increasingly common in complex HS practice.
• Photodynamic therapy for HS — small case series exist; not yet mainstream.

The core recommendation — long-pulsed Nd:YAG 1064 as adjunct to medical management in Hurley I-II HS — has not changed and remains the evidence-supported standard. Confidence: C2.